Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Feb;86(2):e33-e35.
doi: 10.1016/j.jinf.2022.10.026. Epub 2022 Oct 21.

Humoral and cellular responses to the third COVID-19 BNT162b2 vaccine dose in research institute workers in Japan

Affiliations
Comment

Humoral and cellular responses to the third COVID-19 BNT162b2 vaccine dose in research institute workers in Japan

Akihiko Nishikimi et al. J Infect. 2023 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations of Competing Interest The authors declare no competing interests.

Figures

Fig 1
Fig. 1
Humoral and cellular response before and after the third BNT162b2 vaccination dose. (A) Levels of S-IgG in serum on day 0 (n = 86), day 15 (n = 84), day 29 (n = 85), day 61 (n = 83), and day 130–164 (n = 78) after inoculation. (B) Levels of IFN-γ released in response to Ag-1 and Ag-2. Dotted lines indicate the positivity cutoff values. Data are expressed as box plots: middle line, median; box edges, 25th–75th percentile. Statistical comparisons were performed by nonparametric ANOVA, Kruskal–Wallis test.
Fig 2
Fig. 2
Correlation between S-IgG titer and T cell responses before and after the third dose. Correlation between S-IgG levels and IFN-γ levels induced by Ag-1 and Ag-2, respectively, at each point were analyzed by Spearman's rank correlation test. Spearman r and p-values are presented in each graph.

Comment on

References

    1. Mak W.A., Koeleman J.G.M., van der Vliet M., Keuren F., Ong D.S.Y. SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: a prospective cohort study. J Infect. 2022;84:171–178. doi: 10.1016/j.jinf.2021.12.003. - DOI - PMC - PubMed
    1. Nishikimi A., Watanabe K., Watanabe A., Yasuoka M., Watanabe R., Oshima H., et al. Prevalence of SARS-CoV-2 antibodies after one-year follow up among workers in a research institute in Japan. J Infect. 2022;84:e23–e25. doi: 10.1016/j.jinf.2021.10.021. - DOI - PMC - PubMed
    1. Nishikimi A., Watanabe K., Watanabe A., Yasuoka M., Watanabe R., Fujiwara M., et al. Immune responses to COVID-19 vaccine BNT162b2 in workers at a research institute in Japan: 6-month follow-up survey. J Infect. 2022;85:174–211. doi: 10.1016/j.jinf.2022.05.016. - DOI - PMC - PubMed
    1. Aiello A., Coppola A., Vanini V., Petrone L., Cuzzi G., Salmi A., et al. Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay. Int J Infect Dis. 2022;122:841–849. doi: 10.1016/j.ijid.2022.07.049. - DOI - PMC - PubMed
    1. Takeuchi J.S., Fukunaga A., Yamamoto S., Tanaka A., Matsuda K., Kimura M., et al. SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study. Sci Rep. 2022;12:15447. doi: 10.1038/s41598-022-19581-y. - DOI - PMC - PubMed